APVO News and Press, Aptevo Therapeutics Inc. From 08/14/20

Aptevo Therapeutics (NASDAQ: APVO ) : Q2 GAAP EPS of -$2.10 beats by $0.02 . More news on: Aptevo Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

Advances Phase 1/1b Clinical Trial of APVO436 for the Treatment of Acute Myeloid Leukemia and High-Grade Myelodysplastic Syndrome; Cohort 6 Enrollment Complete Presents New Preclinical Data Showing That ALG.APV-527 has Potential for a Favorable Safety Profile Extends Cash ...

Extends Cash Runway into Q3 2021 The Current Cash Balance is Anticipated to Create a Sufficient Timeline to Complete the APVO 436 Phase I(a) Dosing Cohorts Which Pre-Clinical Modelling Predicts May Deliver an Efficacious Dose SEATTLE, WA / ACCESSWIRE / August 6, 2020 / Aptevo Thera...

Aptevo Therapeutics ( APVO +1.9% ) has engaged  Piper Sandler to sell its RUXIENCE and IXINITY royalty streams and milestone payments. More news on: Aptevo Therapeutics Inc., Healthcare stocks news, Read more ...

SEATTLE, WA / ACCESSWIRE / July 21, 2020 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ bispecific technology platform, has engaged Piper Sandler to sell its RUXIENCE ® ...

Aptevo Therapeutics ( APVO +4.6% ) collects in full $0.75M placed into an escrow account for working capital adjustments. More news on: Aptevo Therapeutics Inc., Healthcare stocks news, Read more ...

SEATTLE, WA / ACCESSWIRE / June 29, 2020 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ bispecific technology platform, announced today that it has collected in full the $750,...

Aptevo Therapeutics ( APVO +40.7% ) to receive a seven year quarterly royalty from Pfizer related to sales of RUXIENCE (rituximab biosimilar), which was approved by the FDA in July 2019 and launched by Pfizer in the US and Japan in early 2020. More news on: Apt...

Published Articles Suggest the Global Market for Rituximab Biosimilars Could Potentially be over $1 Billion Per Year Royalty Stream Relates to Agreement Acquired in Aptevo Spin-off from Emergent BioSolutions SEATTLE, WA / ACCESSWIRE / June 25, 2020 / Aptevo Therapeutics Inc. (NA...

New Preclinical Data Show That ALG.APV-527 has Potential for a Favorable Safety Profile Does Not Induce Systemic T-cell Activation at High Doses Which Were Observed in a Urelumab Analogue in a Side-by-Side Comparison ALG.APV-527 is a Novel Immunotherapeutic Bispecific Candidate...